Timolol Metabolism in Human Liver Microsomes Is Mediated Principally by CYP2D6

@article{Volotinen2007TimololMI,
  title={Timolol Metabolism in Human Liver Microsomes Is Mediated Principally by CYP2D6},
  author={Marjo Volotinen and Miia Turpeinen and Ari Tolonen and Jouko Uusitalo and Jukka M{\"a}enp{\"a}{\"a} and Olavi Pelkonen},
  journal={Drug Metabolism and Disposition},
  year={2007},
  volume={35},
  pages={1135 - 1141}
}
Timolol has mainly been used topically for the treatment of glaucoma. It has been suggested that the drug is metabolized by cytochrome P450 CYP2D6. The matter has not, however, been extensively studied. The aim here was to tentatively identify timolol metabolites and to determine the P450-associated metabolic and interaction properties of timolol in vitro. Four metabolites were identified, the most abundant being a hydroxy metabolite, M1. The Km value for the formation of M1 was 23.8 μM in… 

Figures and Tables from this paper

Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes.

It is strongly suggested that fluoxetine and paroxetines may significantly affect the metabolism of timolol also in vivo and may thus potentiate the adverse cardiovascular effects of topically administered timlol.

Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

There is a considerable variability in the CYP2D6 allele distribution among different ethnic groups, resulting in variable percentages of PMs, IMs, EMs and UMs in a given population and the number of alleles is still growing.

Do Cytochrome P450 Enzymes Contribute to the Metabolism of Xenobiotics in Human

The cytochromes P450 (CYP) comprise a large multigene family of hemethiolate proteins which are of considerable importance in the metabolism of xenobiotics and endobiotics. CYP enzymes in humans as

Polymorphism of human cytochrome P450 enzymes and its clinical impact

Current pharmacogenetic knowledge on important human drug-metabolizing cytochrome P450s (CYPs) is highlighted to understand the large interindividual variability in drug clearance and responses in clinical practice and to improve the efficacy and safety of both prospective and currently available drugs.

Metabolism and interactions of pesticides in human and animal in vitro hepatic models

In vitro-in vivo extrapolation based on the elucidation of the in vitro metabolic pattern of pesticides in human and animal hepatic models could be a good model for understanding and extending the results of pesticides metabolism studies to human health risk assessment.

Expression of cytochrome P450 (CYP) enzymes in human nonpigmented ciliary epithelial cells: induction of CYP1B1 expression by TCDD.

TCDD potently induces CYP1B1 mRNA in human nonpigmented ciliary epithelial cells, suggesting the involvement of an AHR-mediated pathway in the regulation of ciliary CYP 1B1 expression.

Paroxetine Markedly Increases Plasma Concentrations of Ophthalmic Timolol; CYP2D6 Inhibitors May Increase the Risk of Cardiovascular Adverse Effects of 0.5% Timolol Eye Drops

Paroxetine and other CYP2D6 inhibitors can have a clinically important interaction with ophthalmic timolol, particularly when patients are using 0.5%Timolol formulations, consistent with the role of CYD6 in the metabolism of both agents.

Effect of CYP2D6*4, CYP2D6*10 polymorphisms on the safety of treatment with timolol maleate in patients with glaucoma

CYP2D 6*4 and CYP2D6*10 gene polymorphisms may affect a higher risk of timolol-induced bradycardia and increased PQ interval of treatment medications containing 0.5% of timOLol maleate in patients with POAG.

Cardiac safety of ophthalmic timolol

A number of factors associated with the properties of ophthalmic timolol and specific features of a patient, which may jeopardize patient’s cardiac safety even after topical treatment are document.

References

SHOWING 1-10 OF 49 REFERENCES

Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate.

Data show that CYP2C8 is the main hepatic isoform responsible for the metabolism of AQ, and the specificity, high affinity, and high turnover make AQ desethylation an excellent marker reaction for CYP1C8 activity.

Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.

ThioTEPA is a drug of choice when high CYP2B6 selectivity among major P450 enzymes is required and ticlopidine is a useful alternative under a controlled experimental setup and when higher potency is needed.

CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.

Bupropion hydroxylation is mediated almost exclusively by CYP2B6 and can serve as an index reaction reflecting activity of this isoform and suggest a low inhibitory potency versus CYP 2D6, the clinical importance of which is not established.

In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene.

Results suggest that tranylcypromine seems an adequately selective CYP2A6 inhibitor for in vitro use and may have at least two P450-related binding sites in liver microsomes.

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

The intricate genetics of the CYP2D6 polymorphism is becoming apparent at ever greater detail, applications in clinical practice are still rare, and more clinical studies are needed to show where patients benefit from drug dose adjustment based on their genotype.

Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.

The results of this study show that both CYP2C19 and CYP3A4 exhibit a stereoselective metabolism of omeprazole, with predictions of the CL(int) using data from cDNA-expressed enzymes suggest that CYP 2C19 is responsible for 40 and 87% of the total CL (int) of S- and R-omeprazole in human liver microsomes.

The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Control studies have shown that debrisoquine oxidation phenotype is a major determinant of the metabolism, pharmacokinetics and some of the pharmacological actions of metoprolol, bufuralol, timolol and bopindolol, and that the disposition of atenolol which is eliminated predominantly unchanged by the kidney and in the faeces, is unrelated tobrisoquine phenotype.

Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.

Results demonstrate selectivity of BUP hydroxylation for CYP2B6 at 500 microM BUP, thereby validating its use as a diagnostic in vitro marker of CYP 2B6 catalytic activity.

The Polymorphic Oxidation of β-Adrenoceptor Antagonists

Debrisoquine oxidation phenotype is a major determinant of the metabolism, pharmacokinetics and some of the pharmacological actions of metoprolol, bufuralol, timolol and bopindolol, and the disposition of atenolol which is eliminated predominantly unchanged by the kidney and in the faeces, is unrelated to debrisoquine phenotype.

Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study

The CYP2D6 poor metabolisers may be more prone to systemic adverse events with aqueous timolol than extensive metaboliers, and the elevation of HR from rest to maximum level tended to differ between PMs and IMs, and between PM and UMs.